BACE (PDF)
Lead Target for Orchestrated Therapy of Alzheimer's Disease
(Sprache: Englisch)
BACE inhibitors and their use in the treatment of Alzheimer's
Disease
BACE (beta-site of APP cleaving enzyme) is a critical
component in Alzheimer's Disease (AD), and the development of BACE
inhibitors shows great potential as a therapy for the...
Disease
BACE (beta-site of APP cleaving enzyme) is a critical
component in Alzheimer's Disease (AD), and the development of BACE
inhibitors shows great potential as a therapy for the...
sofort als Download lieferbar
eBook (pdf)
112.99 €
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenloser tolino webreader
Produktdetails
Produktinformationen zu „BACE (PDF)“
BACE inhibitors and their use in the treatment of Alzheimer's
Disease
BACE (beta-site of APP cleaving enzyme) is a critical
component in Alzheimer's Disease (AD), and the development of BACE
inhibitors shows great potential as a therapy for the disease.
BACE: Lead Target for Orchestrated Therapy of Alzheimer's
Disease covers virtually all aspects of BACE from initial
identification, discovery of inhibitors, and challenges in clinical
development, while providing a global understanding essential for
productive and successful drug discovery.
This book details the story of the discovery of BACE and its
role in AD and comprehensively discusses:
* The development of BACE inhibitors as therapeutics for
Alzheimer's disease
* The research that led to the identification of BACE
* New BACE inhibitors currently being clinically tested
* ADME (absorption, distribution, metabolism, excretion) and
clinical trial design--topics not addressed in current field
literature
* Cutting-edge technology such as high-throughput screening,
structure-based drug design, and QSAR in context of BACE inhibitors
and Alzheimer's drug discovery
* Other approaches to BACE inhibition based on interaction with
the precursor protein APP
By enhancing the reader's understanding of the various aspects
of the BACE drug-discovery process, this much-needed reference will
serve as a key resource for all scientists involved in Alzheimer's
research--and inspire new approaches to treatment of AD.
Disease
BACE (beta-site of APP cleaving enzyme) is a critical
component in Alzheimer's Disease (AD), and the development of BACE
inhibitors shows great potential as a therapy for the disease.
BACE: Lead Target for Orchestrated Therapy of Alzheimer's
Disease covers virtually all aspects of BACE from initial
identification, discovery of inhibitors, and challenges in clinical
development, while providing a global understanding essential for
productive and successful drug discovery.
This book details the story of the discovery of BACE and its
role in AD and comprehensively discusses:
* The development of BACE inhibitors as therapeutics for
Alzheimer's disease
* The research that led to the identification of BACE
* New BACE inhibitors currently being clinically tested
* ADME (absorption, distribution, metabolism, excretion) and
clinical trial design--topics not addressed in current field
literature
* Cutting-edge technology such as high-throughput screening,
structure-based drug design, and QSAR in context of BACE inhibitors
and Alzheimer's drug discovery
* Other approaches to BACE inhibition based on interaction with
the precursor protein APP
By enhancing the reader's understanding of the various aspects
of the BACE drug-discovery process, this much-needed reference will
serve as a key resource for all scientists involved in Alzheimer's
research--and inspire new approaches to treatment of AD.
Autoren-Porträt von Varghese John
VARGHESE JOHN is Director of Alzheimer's Drug Discovery at the Buck Institute for Age Research. He is a chemist with many years of pharmaceutical industry experience in discovery and development of drugs for CNS diseases with a primary focus on Alzheimer's disease (AD). Dr. John has many publications and patents to his credit.
Bibliographische Angaben
- Autor: Varghese John
- 2010, 1. Auflage, 272 Seiten, Englisch
- Verlag: John Wiley & Sons
- ISBN-10: 0470594071
- ISBN-13: 9780470594070
- Erscheinungsdatum: 31.03.2010
Abhängig von Bildschirmgröße und eingestellter Schriftgröße kann die Seitenzahl auf Ihrem Lesegerät variieren.
eBook Informationen
- Dateiformat: PDF
- Größe: 10 MB
- Mit Kopierschutz
Sprache:
Englisch
Kopierschutz
Dieses eBook können Sie uneingeschränkt auf allen Geräten der tolino Familie lesen. Zum Lesen auf sonstigen eReadern und am PC benötigen Sie eine Adobe ID.
Kommentar zu "BACE"
Schreiben Sie einen Kommentar zu "BACE".
Kommentar verfassen